BENEFIT Extension Study

To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Nervous System Diseases

Age range

23 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Many Locations, Austria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients randomized and treated at least once in study 304747

Exclusion criteria

Medical, psychiatric or other conditions that compromise the patient's ability to understand the purpose of the study

Treatment and study plan

Interferon beta-1b (Betaseron, BAY86-5046)

Drug

Standard Therapy for Multiple Sclerosis

Primary outcomes

To obtain further clinical data of patients with a first demyelinating event suggestive of Multiple Sclerosis enrolled in the BENEFIT Study

Time frame: End of Study

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Extension Study of the BENEFIT (304747) and BENEFIT Follow-up (305207) Studies to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis

Important dates

Study start: 2007
Primary completion: 2011
Study completion: 2011
First posted: Oct 16, 2007
Registry last updated: Mar 5, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed